Bird Flu Fears Mount in China as Herbal Remedies Run Out

Bird Flu Fears Mount in China as Herbal Remedies Run Out

A popular herb called ban lan gen, or blue root, has been flying off pharmacy shelves across China as local governments encourage people to consider traditional remedies to ward off the latest bird flu virus.

With scientists so far unable to pinpoint the H7N9 influenza virus’ animal host, locals are preparing for a possible pandemic by stocking up on popular plant remedies as well as face masks and hand sanitizers and other over-the- counter remedies.

“Chinese people associate ban lan gen with anti-virus,” said Shen Jiangang, assistant director for research at the University of Hong Kong’s school of Chinese medicine. “So when they hear about bird flu, they immediately think it might be effective to protect themselves although there is no experimental evidence.”

Ayurvedic and Chinese medicines have used the remedy for centuries. Scientists have proved it can relieve bacterial conjunctivitis in eye drops and found it has an antiviral effect in test tubes. There is no test to show it works against influenza.

That hasn’t stopped buyers. Chinese consumers, especially older ones, tend to believe in traditional formulations especially when it comes to cold and flu remedies, said Iwona Mamczur, an analyst at Mintel International Group Ltd. The market for over-the-counter medicines was worth 77.5 billion yuan ($12.5 billion) in 2011, according to a report from the London-based researcher.Warm Drink

Ban lan gen is the root of a flowering plant known as dyer’s woad or indigo woad, and found in southeastern Europe, central Asia and eastern Siberia. The roots are dried and often processed into granules, which consumers ingest dissolved in hot water or tea. According to traditional Chinese medicine, which seeks to balance heat and cold in the body, the root can help clear the heat triggered by a viral attack, Shen said.

Huashi Pharmacy, located in Shanghai near the eastern bank of the Huangpu river, has started replenishing supplies of ban lan gen daily instead of weekly and still struggles to meet demand, according to pharmacy worker Zhang Zhijin.

Sales of facial masks have also gone up 10 times from before the H7N9 infections announcements, hand sanitizer has sold out, and companies have been bulk-ordering alcohol wipes for their employees, Zhang said.

Face Masks

Beijing Tongrentang (600085), which makes a product extracted from ban lan gen, said in an e-mail that the outbreak of H7N9 has boosted sales, but didn’t provide numbers.

Francis Chu, the Singapore-based inventor of the totobobo face mask, said he’s fielded more than 20 inquiries about the pollution-filtering equipment’s effectiveness against bird flu since the start of April. Sales are up eight-fold from the same period last year.

“Earlier in the year, most of the increased orders from China were because of the air pollution,” Chu said in a telephone interview. “Sales are still increasing, but now it’s because of worries about bird flu.”

Beyond anecdotal evidence, the surge is hard to quantify. Pharmaceutical companies reaped at least $10 billion in sales of vaccines and antivirals globally as a result of the 2009 swine flu outbreak, according to data compiled by Bloomberg at the time. It’s too early to tell whether H7N9 will touch off another pandemic.

No Immunity

Chinese authorities are struggling to identify the source and mode of transmission of the virus, which has sickened 77 people and killed 16 so far, most of them in China’s eastern provinces. While there is no evidence that H7N9 is spreading easily among people, it hasn’t been detected in humans before, so they have no natural immunity. That raises public health concerns, researchers at the Centers for Disease Control and Prevention in Atlanta said last week.

Sinovac Biotech Ltd. (SVA), the first company to win regulatory approval for a swine flu shot in 2009, is preparing to make immunizations against the new virus, Chief Executive Officer Yin Weidong said in an interview Monday. The Nasdaq-traded company could have a first batch of the vaccine ready for commercial use by late July in the event of a pandemic, according to Yin.

Until such a vaccine is found, the race is on for Chinese citizens to track down the ban lan gen herb.

Zheng Bing, who works as an assistant at a local private equity firm, recently walked away empty-handed from three separate pharmacies in Beijing’s financial district. Zheng was told by his boss to stock up on the herb for the entire office. But he found that other anxious residents had beat him to the punch.

“I’m going to try a few more shops,” he said. “Otherwise I can’t answer my boss.”

To contact Bloomberg News staff for this story: Natasha Khan in Hong Kong at nkhan51@bloomberg.net; Daryl Loo in Beijing at dloo7@bloomberg.net; Jack Gao in Shanghai at ygao40@bloomberg.net

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment